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Abstract
Background: Fenretinide (4-HPR) is a synthetic retinoid that exhibits potent antitumor and chemopreventive activities
against different malignancies, including ovarian tumors. We previously showed that in ovarian cancer cells, 4-HPR induces
apoptosis through a signaling cascade starting from reactive oxygen species (ROS) generation and involving endoplasmic
reticulum (ER) stress response, Jun N-terminal Kinase (JNK) activation, and induction of the proapoptotic PLAcental Bone
morphogenetic protein (PLAB). Since recent studies have shown that the oncogene ALL1-fused from chromosome 1q
(AF1q), a retinoic acid target gene, is implicated in apoptosis induction by several therapeutic agents, we investigated its
possible involvement in the apoptosis induced by 4-HPR in ovarian cancer cells.
Methodology/Principal Findings: Protein expression analysis, performed in ovarian cancer cells and extended to other
histotypes (breast, neuroblastoma, and cervical), revealed that 4-HPR enhanced AF1q expression in cancer cells sensitive to
the retinoid but not in resistant cells. Through gene silencing, AF1q was found functionally involved in 4-HPR-induced
apoptosis in A2780, an ovarian cancer cell line highly sensitive to retinoid growth inhibitory and apoptotic effects. Inhibition
of the signaling intermediates of the 4-HPR apoptotic cascade showed that AF1q upregulation was depended on prior
generation of ROS, induction of ER stress response, JNK activation, and PLAB upmodulation. Finally, we found that direct
overexpression of AF1q, in the absence of external stimuli, increased apoptosis in ovarian cancer cell lines.
Conclusions/Significance: The study expands the knowledge of the 4-HPR mechanism of action, which has not yet been
completely elucidated, identifying AF1q as a novel mediator of retinoid anticancer activity. In addition, we demonstrate, for
the first time, that AF1q plays a role in the onset of basal apoptosis in ovarian cancer cells, thus providing new information
about the activity of this protein whose biologic functions are mostly unknown.
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Introduction
Retinoids, a large family of natural and synthetic compounds
structurally related to vitamin A (retinol), are essential signaling
molecules that regulate a wide variety of biological processes such
as embryonic development, differentiation, maintenance of
epithelial tissue, reproduction, vision, proliferation and apoptosis
[1,2]. N-(4-hydroxyphenyl)retinamide (4-HPR), also known as
fenretinide, is a synthetic vitamin A derivative well tolerated in
humans that has emerged as one of the most promising retinoids in
the clinic for prevention and treatment of numerous malignancies
[3–7]. 4-HPR has been shown to possibly reduce the occurrence of
ovarian cancer and to determine, in premenopausal women, a
significant reduction in the risk of a second breast cancer that
persists for at least 15 years [3,6]. Even though 4-HPR
mechanisms of action has been an important focus of research
over the last decade, the molecular events mediated by the retinoid
appear multifaceted and have not been completely elucidated [8].
Unlike classical retinoids (such as all-trans retinoic acid), that often
induce differentiation and/or cytostasis by activating the family of
nuclear retinoic acid receptors (RARs), 4-HPR has been shown to
elicit different biological effects through both retinoid receptor–
dependent and –independent mechanisms [9].
In cultured cells, 4-HPR has been shown to inhibit cell
proliferation and to promote apoptosis mediated, at least in part,
by the generation of reactive oxygen species (ROS) and
consequent oxidative stress [8–11]. We previously provided
evidence that, in ovarian cancer cells, 4-HPR induced apoptosis
through a signaling cascade starting from ROS production and
involving endoplasmic reticulum (ER) stress response, Jun N-
terminal Kinase (JNK) activation, and induction of the proapop-
totic PLAcental Bone morphogenetic protein (PLAB, also known
as NAG-1, GDF15, MIC-1, PDF, and PTGFB) (ROS R ER stress
R JNK R PLAB) [11,12].
The ALL1-fused from the chromosome 1q (AF1q, also known
as MLLT11) gene, located in chromosome 1, band 21, encodes a
small protein of 9 kDa with no well-defined functional domains
and no similarity to other known proteins [13]. The mechanisms
underlying the regulation of AF1q expression have been
investigated at mRNA and protein levels. An increase in AF1q
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neuroblastoma cells after exposure to the retinoid, thus
identifying AF1q as a RA-target gene [14]. More recently, it
has been demonstrated that AF1q mRNA expression is directly
regulated by microRNA29b [15], whereas the protein is
subjected to ubiquitin-mediated degradation by the proteasome
in the centrosomal area [16]. AF1q was originally defined as an
oncogenic factor implicated in a translocation t(1;11)(q21;q23)
responsible for cases of leukemia [13]. Moreover, a high
expression level of the gene was reported to be associated with
a poor outcome in pediatric acute myeloid leukemia (AML),
adult normal cytogenetic AML, and adult myelodysplastic
syndrome [17–19]. Although the biological functions of AF1q
are largely unknown, a potential oncogenic function of the
protein has also been suggested in solid tumors such as breast
cancer and thyroid oncocytic and testicular germ cell tumors
[20–23]. In addition to the proposed oncogenic role of AF1q, it
has been reported that the protein may regulate the BAD-
mediated apoptotic pathway via NF-kB, thus playing a role in
the regulation of apoptosis and in drug resistance [24,25]. A
decrease in AF1q expression in conjunction with reduced
doxorubicin sensitivity has been observed in human squamous
carcinoma cells, and knockdown of the protein has been shown
to decrease apoptotic cell death induced by several therapeutic
agents, such as doxorubicin and c radiation [24,25].
The present study investigated the involvement of AF1q in 4-
HPR-induced apoptosis in ovarian tumor cells. We provide
evidence that 4-HPR treatment enhances AF1q expression levels
in cancer cells sensitive to the retinoid and that such upregulation
is an important event of the 4-HPR signaling cascade that leads to
apoptosis through ROS generation, ER stress response, JNK
activation, and PLAB upregulation. Finally, by AF1q overexpres-
sion, we demonstrated a role of AF1q in the onset of basal
apoptosis in ovarian cancer cells.
Results
4-HPR Induces AF1q Upregulation in Ovarian Cancer
Cells Sensitive to the Retinoid but not in Resistant Cells
Since AF1q was shown to play a role in the apoptosis induced
by several therapeutic agents and to be regulated by RA
[14,24,25], we sought to investigate the potential contribution of
the protein in the apoptotic activity of the synthetic retinoid 4-
HPR. We analyzed the effect of 4-HPR treatment on AF1q
expression in the human ovarian cancer cell line A2780, which is
highly sensitive to the antiproliferative and apoptotic effects of the
retinoid [26,27], and in its counterpart A2780/HPR, which has
induced resistance to 4-HPR [28]. Protein expression analysis
showed that A2780 cells constitutively expressed AF1q protein and
that treatment with 5 and 10 mM 4-HPR for 24 hours increased its
expression in a dose-dependent manner (Figure 1A). In contrast, 4-
HPR treatment did not cause any increase in AF1q protein
expression in A2780/HPR cells, even though the cells constitu-
tively expressed it (Figure 1B). Such data suggested an association
between AF1q induction by 4-HPR treatment and cell sensitivity
to the retinoid.
4-HPR Enhances AF1q Expression in Other Ovarian
Cancer Cells and in Cancer Cell Lines of Different
Histotypes
To assess whether 4-HPR-induced AF1q upregulation was
restricted to A2780 cells or represented a distinctive mode of
action of the retinoid, we extended the analysis of AF1q expression
to others human cancer cells with different sensitivities to the
antiproliferative effect of 4-HPR. Treatment with 5 mM 4-HPR
for 24 hours induced AF1q upregulation in the sensitive ovarian
cancer cell lines OVCA432 and SKOV-3 [27] (Figure 2A), as well
as in responsive cells of different histotypes, i.e., mammary
adenocarcinoma T47D and neuroblastoma SK-N-BE [27]
(Figure 2B). In contrast, in cells naturally resistant to 4-HPR
growth inhibitory activity such as the ovarian cancer cell line
OVCAR-3 [27] and the cervical carcinoma cell lines HeLa
(IC50.10 mM, at 72 hours, data not shown), neither 5 mM (data
not shown) nor 10 mM 4-HPR treatment for 24 hours caused
upmodulation of AF1q expression (Figure 2C). The results
suggested that 4-HPR-induced AF1q upregulation did not occur
only in A2780 cells but was a characteristic of cancer cells
responsive to the retinoid.
AF1q Upregulation in A2780 Cells is Associated to
Retinoid Ability to Inhibit Cell Growth and Induce
Apoptosis
Analysis of the association between AF1q expression and
tumor growth inhibitory and apoptotic effects was extended to
other natural and synthetic retinoids, i.e., RA, and N-(4-
methoxyphenyl)retinamide (4-MPR) and 4-oxo-N-(4-hydroxyphe-
nyl)retinamide (4-oxo-4-HPR), two 4-HPR metabolites. We
previously demonstrated that 4-oxo-4-HPR has a growth
inhibitory effect (IC50=0.6 mM, at 72 hours) and induces
apoptosis in A2780 cells, whereas 4-MPR and RA do not affect
such growth (IC50.10 mM, at 72 hours for both retinoids) [27–
29]. As shown in Figure 3, in A2780 cells the treatment with RA,
Figure 1. Effects of 4-HPR on AF1q expression in A2780 and
A2780/HPR cells. Western blot analysis for AF1q expression in A2780
(A) and A2780/HPR (B) cells treated for 24 hours with 5 and 10 mM4 -
HPR. As a control for loading, the blots were incubated with actin
antibody.
doi:10.1371/journal.pone.0039968.g001
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caspase-3 activation, whereas 4-oxo-4-HPR treatment led to an
increase in AF1q expression and to caspase-3 cleavage (Figure 3).
The data demonstrated that retinoid-induced AF1q upregulation
was associated with the ability of the compound to inhibit cell
growth and to induce apoptosis.
AF1q Upregulation is Functionally Involved in Apoptosis
Induced by 4-HPR in A2780 Cells
To study the potential role of AF1q in 4-HPR-mediated
apoptosis, we performed AF1q silencing by transient transfections
of A2780 cells with a plasmid expressing an AF1q siRNA or a
scrambled nonsilencing siRNA used as control. Transfection with
AF1q siRNA reduced both basal and 4-HPR-induced AF1q
expression and clearly decreased 4-HPR-induced apoptosis, as
shown by cleavage of caspase-3 (Figure 4), demonstrating that
AF1q played a role in apoptosis induction by 4-HPR in A2780
cells. Under the same experimental conditions, we did not observe
modulation of the proapoptotic protein BAD (Figure 4), previously
shown to be regulated by AF1q in human squamous carcinoma
cells [24,25].
AF1q is Involved in the Apoptotic Signaling Cascade
Induced by 4-HPR in A2780 Cells
We previously reported that 4-HPR-induced apoptosis occurs
through a signaling cascade involving ROS generation, ER stress
induction, JNK activation and PLAB upregulation (ROS R ER
stress R JNK R PLAB) [11,12]. We thus evaluated whether AF1q
was involved in the aforementioned apoptotic pathway by testing
the effects of the inhibition of these signaling intermediates on 4-
HPR-induced AF1q upmodulation. To this aim, A2780 cells were
co-treated with 4-HPR and, in turn, with the antioxidant vitamin
C, the ER stress inhibitor salubrinal, and the pharmacological
JNK inhibitor SP600125, which have been demonstrated to
prevent ROS generation, eIF2a dephosphorylation, and JNK
activation, respectively, and to strongly reduce 4-HPR-induced
Figure 2. Effects of 4-HPR treatment on AF1q expression in a
panel of cancer cell lines. Western blot analysis for AF1q expression
in OVCA432 and SKOV-3 (A) cells, in T47D and SK-N-BE (B) cells, and in
OVCAR-3 and HeLa (C) cells treated for 24 hours with 4-HPR at the
indicated doses. As a control for loading, the blots were incubated with
actin antibody.
doi:10.1371/journal.pone.0039968.g002
Figure 3. Effects of different retinoids on AF1q expression in
A2780 cells. Western blot analysiso for AF1q expression and caspase-3
cleavage in A2780 cells treated for 24 hours with 10 mM RA or 4-MPR, or
3 mM 4-oxo-4-HPR. As a control for loading, the blot was incubated with
actin antibody.
doi:10.1371/journal.pone.0039968.g003
Figure 4. Role of AF1q upmodulation in 4-HPR-induced
apoptosis. Western blot analysiso for AF1q expression, caspase-3
cleavage, and BAD expression in A2780 cells transiently transfected
with a plasmid containing a AF1q siRNA or a scrambled nonsilencing
siRNA following addition of 5 mM 4-HPR for 24 hours. As a control for
loading, the blot was incubated with actin antibody.
doi:10.1371/journal.pone.0039968.g004
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vitamin C to A2780 cells treated with 5 mM 4-HPR for 24 hours
abrogated the 4-HPR-induced upregulation of AF1q (Figure 5A).
Similarly, the addition of 10 mM salubrinal or 10 mM SP600125
strongly reduced 4-HPR-induced AF1q upregulation (Figure 5B
and 5C). To investigate whether the upregulation of AF1q was a
downstream event also of PLAB upregulation induced by 4-HPR,
PLAB has been knocked down using a synthetic siRNA targeting
PLAB mRNA. As shown in Figure 5D, the treatment of A2780
cells with the PLAB-specific siRNA was able to strongly reduce 4-
HPR-induced PLAB as well as AF1q upmodulation compared
with the cells transfected with a control siRNA. Conversely, AF1q
silencing did not affect 4-HPR-induced PLAB upregulation
(Figure 5E). The aforementioned data indicated that in A2780
cells AF1q upregulation was dependent on prior activation of the
4-HPR-induced-ROS-related signaling cascade and that its
upmodulation occurred downstream of PLAB induction (Figure 6).
AF1q Plays a Role in the Induction of Basal Apoptosis in
Ovarian Cancer Cells
To investigate the link between AF1q induction and apoptosis
onset, we analyzed whether direct overexpression of AF1q, in the
absence of external stimuli, could cause apoptosis. To this aim,
A2780 cells were transiently transfected with a Green Fluorescent
Protein (GFP)-tagged AF1q vector. Cells transfected with a vector
coding for GFP were used as control. At 48 hours after
transfection, nuclear fragmentation and chromatin condensation
were monitored in green fluorescent cells by staining cell nuclei
with Hoechst 33342 (Figure 7A). As shown in Figure 7B (left
panel), GFP-AF1q-overexpressing cells showed a marked increase
in apoptotic nuclei relative to control cells transfected with GFP
alone. A similar effect was observed when the analysis was
performed in OVCAR-3 cells, another ovarian cancer cell line
that, differently from A2780 cells, was resistant to the 4-HPR
antiproliferative effect and did not constitutively express AF1q.
Transfection with GFP-AF1q induced also in OVCAR-3 an
increase in basal apoptosis relative to transfection with GFP
(Figure 7B, right panel). These findings suggested a role for AF1q
in the onset of apoptosis in ovarian cancer cells.
Discussion
The recent findings that the AF1q gene, beside its documented
oncogenic function [17–23], plays a role in apoptosis regulation in
cancer cells [24,25] and the fact that it has been described as an
RA-target gene [14], prompted us to investigate its possible
involvement in apoptosis induced by the synthetic nonclassic
retinoid 4-HPR. The present study identified AF1q as a novel
mediator of apoptosis induced by 4-HPR and provided evidence
of a role of the protein in the onset of basal apoptosis in ovarian
cancer cells. We showed that in A2780, a human ovarian
carcinoma cell line highly sensitive to the growth inhibitory and
apoptotic effects of the retinoid [26,27], 4-HPR-induced apoptosis
was accompanied by an increase in AF1q protein expression. In
contrast, the upmodulation of AF1q was not observed when
A2780/HPR cells, a 4-HPR resistant variant derived from A2780
cells [28], were treated with the retinoid. Analysis of AF1q
expression, extended to a panel of human cancer cell lines
(ovarian, breast, cervical, and neuroblastoma) with different
sensitivities to the 4-HPR antiproliferative effect [27], confirmed
that upmodulation of the protein after 4-HPR exposure was a
common feature of 4-HPR responsive cells but did not occur in
cancer cells resistant to the retinoid.
The association between cell sensitivity to 4-HPR anticancer
effects and AF1q upregulation suggested a role for AF1q as a
putative mediator of 4-HPR activity. The hypothesis was also
supported by the fact that AF1q expression was selectively
Figure 5. Relationship between AF1q upregulation and 4-HPR-
induced signaling cascade. Western blot analysis for AF1q
expression in A2780 cells treated for 24 hours with 5 mM 4-HPR, with
or without 100 mM vitamin C (A), 10 mM salubrinal (B), or 10 mM
SP600125 (C). (D) Western blot analysis for AF1q expression in A2780
cells stably transfected with a plasmid containing a PLAB siRNA or a
scrambled nonsilencing siRNA following addition of 5 mM 4-HPR for 24
hours. As a control for loading, the blots were incubated with actin
antibody.
doi:10.1371/journal.pone.0039968.g005
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HPR, but not by RA or 4-MPR, which failed to induce cell
death in A2780 cells [27–29]. The lack of induction of AF1q and
apoptosis after challenging the cells with RA is consistent with
the issue that 4-HPR biological effects and the mechanisms
underlying its anticancer activities greatly differ from those of
classical retinoids [9] and are instead more close to those
described for atypical retinoids [30]. A direct link between AF1q
upregulation and apoptosis induced by 4-HPR was demonstrated
by AF1q silencing, which led to a reduction in 4-HPR-induced
apoptosis, thus indicating that AF1q is, at least in part,
responsible for the apoptotic effects caused by the retinoid in
ovarian cancer cells.
We previously showed that 4-HPR was able to cause apoptosis
in ovarian cancer cells through the activation of the ROS R ER
stress R JNK R PLAB signaling cascade [11,12]. Induction of
such a cascade was characteristic only of cancer cells responsive to
4-HPR and was not activated in 4-HPR-resistant cells [12]. We
thus hypothesized that 4-HPR-induced upregulation of AF1q,
which occurred only in cells sensitive to the retinoid, could be an
intermediate of the aforementioned apoptotic pathway. Consistent
with this hypothesis, we found that the upregulation of AF1q
occurred downstream of ROS generation, ER stress response,
JNK activation, and PLAB upregulation induced by 4-HPR. In
fact, by inhibiting the pathway at different levels using in turn the
antioxidant vitamin C, the selective inhibitor of eIF2a dephos-
phorylation salubrinal, and the JNK inhibitor SP600125 (all
previously proved to protect A2780 cells from 4-HPR-induced
apoptosis [12]), we showed that 4-HPR-induced AF1q upregula-
tion was strongly reduced. Moreover, silencing of the proapoptotic
protein PLAB (previously shown to reduce 4-HPR-induced
apoptosis [11]) caused a decreased ability of the retinoid to
increase AF1q expression. Conversely, AF1q silencing did not
affect the ability of 4-HPR to induce PLAB upregulation The
aforementioned results demonstrated that AF1q was an interme-
diate of the ROS-related signaling cascade activated by 4-HPR to
induce apoptosis and that AF1q upmodulation occurred down-
stream of PLAB induction (Figure 6). However, the contribution of
other ROS-dependent signals to the 4-HPR-induced AF1q
upmodulation cannot be excluded. Not surprisingly, we found
that AF1q was upregulated also after treatment with 4-oxo-4-
HPR, a 4-HPR polar metabolite able to activate the aforemen-
tioned apoptotic cascade (from ROS generation to PLAB
induction) [31].
In agreement with our observations, analysis of one publicly
available microarray experiment dataset on 4-HPR-treated and
untreated CD34+ cells from four chronic myeloid leukemia
patients (GEO Accession: GSE17480) showed that the retinoid
induced a six-fold increase in AF1q mRNA expression (P,0.01)
(Figure S1). In the same cells, 4-HPR was able to induce apoptosis
- suggested to be mediated by the induction of oxidative stress,
thus confirming the relationship between ROS mediated-apoptosis
induced by 4-HPR and AF1q overexpression.
According to the apoptotic role suggested by our observations,
AF1q involvement in apoptosis regulation and in drug resistance
has been reported by another research group [24,25]. The authors
showed that in human squamous carcinoma cells, AF1q down-
regulation was associated with a doxorubicine-resistant cell
phenotype and that AF1q upmodulation caused an increased
doxorubicin and c radiation-induced apoptosis through transacti-
vation of the proapoptotic protein BAD via NF-kB [24,25]. In
contrast, we did not observe upregulation of BAD in AF1q-
mediated apoptosis induced by 4-HPR in A2780 cells. In fact, 4-
HPR treatment did not modulate BAD expression, nor did AF1q
silencing cause changes in its protein levels. One possible
explanation could be that AF1q might differently affect BAD
expression in different cancer cell types and/or in response only to
specific stimuli. However, it is interesting to note that, as for 4-
HPR and 4-oxo-4-HPR [12,31], doxorubicin and c radiation-
induced apoptosis has also been reported to be associated to ROS
generation [32–34]. Therefore, it is tempting to speculate that
AF1q-mediated apoptosis could depend on prior induction of
oxidative stress, not only for 4-HPR and 4-oxo-4-HPR but also for
other chemotherapeutic agents, although at present no sufficient
evidence supports such a hypothesis.
An important finding of our study is the indication of a role of
AF1q in the onset of basal apoptosis: AF1q upmodulation
obtained by transient transfection in ovarian cancer cells caused,
in the absence of external stimuli, an increase in the apoptotic
rate, thus demonstrating a role of AF1q in actively inducing
apoptosis in these cells. A comprehensive understanding of the
precise physiological and pathological functions of AF1q is
definitely in its infancy. However, the few studies that have
investigated its role revealed that it might be implicated in both
inhibition and promotion of cancer progression [17–25]. In
addition to evidence of a role as an apoptosis mediator, AF1q
has been defined as an oncogenic factor involved in hematolog-
ical malignancies as well as in solid tumors [17–23]. It is
noteworthy to observe that, similarly to that reported for AF1q,
PLAB has also been shown to be endowed with a dual function
in cancer progression [35]. In fact, this member of the
transforming growth factor-b superfamily can in fact negatively
or positively modulate cell proliferation and apoptosis and may
Figure 6. Scheme showing proposed cascade of events
involved in 4-HPR-induced growth inhibitory effect. 4-HPR
induces apoptosis through a signaling cascade involving oxidative
stress, ER stress response, JNK activation, overexpression of the
proapoptotic protein PLAB, and AF1q upregulation.
doi:10.1371/journal.pone.0039968.g006
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though the mechanisms regulating the pleiotropic functions of
PLAB are still not well understood, it has been proposed that the
protein can act as a tumor suppressor in the early stages of
malignancy, whereas it can promote tumor progression in
advanced stages of cancer [35]. An intriguing consideration is
Figure 7. Effect of AF1q overexpression in the onset of basal apoptosis. (A) Immunofluorescence analysis of A2780 cells transiently
transfected with GFP alone (upper panels) or GFP-tagged AF1q vector (AF1q-GFP) (lower panels). After 48 hours, GFP and AF1q-GFP cells were
stained with Hoechst 33342 and nuclear morphology was examined with a fluorescent microscope. Cells of interest are marked by arrows. Cells with
condensed and fragmented nuclei were identified and scored as apoptotic cells. One experiment representative of three is shown. The scale bar
represents 10 mm. (B) Apoptosis was represented as percentage of apoptotic cells per 100 green fluorescent cells (at least 200 cells per sample) in
A2780 (left panel) and OVCAR-3 (right panel) cells transfected as in (A). Data represent the mean6S.D. of three independent experiments. Asterisks
indicate significant difference (P,0.05).
doi:10.1371/journal.pone.0039968.g007
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both RA-target genes and are able to induce apoptosis in the
absence of external stimuli [11,36]. Although further studies are
necessary to define the exact functions of AF1q and to investigate
the possible association between PLAB and AF1q, the present
data demonstrate for the first time a relationship between these
two proteins.
In conclusion, our study expands the knowledge of the
mechanisms of action of 4-HPR that, even though investigated
for many years, have not yet been completely elucidated [8]. The
identification of novel targets of the retinoid is an important issue
because it might lead to facilitate future design of drug
combination strategies and to overcome and prevent the
development of drug resistance. In addition, we provide new
information about the activity of AF1q, a cancer-related protein
whose biological functions are largely unknown. Specifically, we
report that AF1q is involved in 4-HPR apoptotic and growth
inhibitory effects and that its upregulation depends on the
activation of the ROS-related signaling cascade induced by the
retinoid, thus discovering a novel relationship between oxidative
stress and AF1q. Finally, we demonstrate for the first time a role
for AF1q in the induction of basal apoptosis in ovarian cancer
cells, although additional studies are needed to define the
molecular mechanisms underlying AF1q-mediated apoptosis.
Materials and Methods
Cell Lines and Reagents
The ovarian tumor cell lines A2780 (obtained from Dr. Ozols,
Bethesda, MD, USA) [31], OVCA432 (obtained from Dr. Knapp,
Boston, MA, USA) [12], OVCAR-3 [12], SKOV-3 [12], and the
neuroblastoma cell line SK-N-BE (all three purchased from
ATCC, Manassas, VA, USA) [31] were maintained in RPMI
1640 (Lonza, Basel, Switzerland) containing 10% fetal calf serum.
A2780/HPR (i.e., A2780 cells made resistant to 4-HPR as
previously described [28]) cells were maintained in RPMI 1640
containing 10% fetal calf serum supplemented with 5 mM 4-HPR.
The breast tumor cell line T47D (obtained from Dr. R.
Sutherland, Sydney, New South Wales, Australia) [31] was
maintained in RPMI 1640 containing 10% fetal calf serum and
0.25 U/ml insulin. The cervical carcinoma cell line HeLa,
purchased from ATCC [31], was maintained in Dulbecco’s
Modified Eagle medium (Gibco Brl, Paisley, UK) supplemented
with 10% fetal calf serum. All cell lines were cultured at 37uC
under 5% CO2. 4-HPR, 4-MPR (both kindly provided by Dr. J.
Crowell, National Cancer Institute, Bethesda, MD, USA), RA
(purchased from Sigma, St Louis, MO, USA), and 4-oxo-4-HPR
(synthesized as previously described [29]) were dissolved at 10 mM
in DMSO, prior to dilution in culture medium and stored at –
80uC in the dark. Vitamin C (Sigma) and JNK inhibitor SP600125
(Calbiochem, San Diego, CA, USA) were added to cells 60
minutes and 15 minutes before 4-HPR, respectively. ER stress
response inhibitor salubrinal (Calbiochem) was added together
with 4-HPR.
Immunoblot Analysis
Proteins were extracted by lysing cells in sodium dodecyl sulfate
(SDS) sample buffer (62.5 mM Tris–HCl [pH 6.8], 2% SDS)
containing 1 mM phenylmethylsulfonyl fluoride, 10 mg/mL pep-
statin, 12.5 mg/mL leupeptin, 2 mg/mL aprotinin, 1 mM sodium
orthovanadate, and 1 mM sodium molybdate. Cell extracts were
processed for western immunoblotting as previously described
[37]. The following antibodies used for immunoblotting were
purchased from the indicated suppliers: AF1q from Abnova
(Taipei City, Taiwan, #H00010962-M01); cleaved Caspase-3
(Asp175) from Cell Signaling Biotechnology (Beverly, MA, USA,
#9661); BAD from Transduction Laboratories (Lexington, KY,
USA, #610391); PLAB from R&D Systems (Minneapolis, MN,
USA, #BAF940); and actin from Sigma (#A2066).
Immunofluorescence Analysis
Cells, grown and transfected on glass coverslip slides in 24 mm
Petri dishes, were fixed in 4% paraformaldehyde at room
temperature for 10 minutes, washed with PBS and then stained
with Hoechst 33342 (Sigma) 2 mg/ml in PBS for 2 minutes. Slides
were mounted with 0.1% (v/v) Mowiol (Calbiochem) and viewed
with a fluorescence microscope [images were recorded with a Spot
Insight digital camera (Delta Sistemi) equipped with a system of
image analysis (IAS 2000; Delta Sistemi)]. Apoptotic cells were
identified by analysis of nuclear morphology. Green florescent cells
with condensed and fragmented nuclei were identified and scored
as apoptotic cells (at least 200 cells per sample).
Construction of GFP-tagged AF1q Expression Vector
AF1q was transiently expressed as a fusion protein with the GFP
fused to its C-terminal. AF1q coding the cDNA region deprived of
the stop codon was obtained by Polymerase Chain Reaction
(PCR) amplification from a plasmid containing the cDNA
encoding human AF1q obtained from the Integrated Molecular
Analysis of Genomes and their Expression (I.M.A.G.E.) Consor-
tium (Livermore, CA, USA) (cDNA clone IMAGE:305990). We
used the forward oligonucleotide primer 59-ACTCGAGCCAC-
CATGAGGGACCCTGTGAG-39 [which contains an XhoI
restriction site and a Kozak sequence (CCACC)], and the reverse
oligonucleotide primer 59-ATCCGGATCCAGCAAGTC-
CAGTTCG -39 (which contains a BamHI restriction site). The
amplification reaction was initiated by incubation of the sample at
94uC for 2 minutes, followed by 15 cycles consisting of incubation
at 94uC for 30 s, at 45uC for 60 s and 68uC for 90 s and by 20
cycles at 94uC for 60 s and 68uC for 90 s. The resultant PCR
fragment was digested with XhoI and Bam HI and ligated in
frame with the GFP gene into the expression vector pEGFP-N1
(Clontech, Palo Alto, CA, USA), previously digested with the same
enzymes.
AF1q Knockdown
Cells (5610
5) were seeded in 60 mm dishes; 24 hours later, a
mixture of Lipofectamine 2000 reagent (Invitrogen, San Diego,
CA, USA) and 8 mg of expression plasmid was added and then
incubated for 6 hours. Cells were then cultured in medium
supplemented with 10% serum for an additional 48 hours before
further analysis. Plasmids expressing a AF1q siRNA and a
scrambled nonsilencing siRNA were purchased from Origene
(Rockville, MD, USA, #TF319110).
PLAB Knockdown
A2780 cells were transfected with a synthetic PLAB siRNA and
with a All Stars Negative Control siRNA (from the Flexitube Gene
Solution siRNA kit of Qiagen, Milan, Italy, #GS9518 and
#SI03650318). Transfections were performed using 32 nM
siRNA in OptiMEM medium (Invitrogen) with Lipofectamine
2000 (1%, v/v), following the manufacturer’s instruction. Forty-
eight hours post-transfection, the cells were treated or not with
5 mM 4-HPR for 24 hours and PLAB knockdown was confirmed
by Western blot analysis.
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Experiments were carried out at least in triplicate. Differences
between mean values were assessed by Student’s t-test with two-
sided P values ,0.05 considered as statistically significant.
Supporting Information
Figure S1 AF1q expression in CD34+ cells from CML
patients with or without 4-HPR treatment. AF1q expres-
sion levels were extracted from the GSE17480 dataset, where the
expression profile of CD34+ cells from CML patients after
treatment or not with 4-HPR was reported. Using a paired t-test,
AF1q expression was found to be significantly higher in 4-HPR
treated cells.
(TIF)
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